53.9 F
New York
Friday, September 30, 2022



Vesalio Announces FDA Approval of the NeVa VS™ to Treat Cerebral Vasospasm After Aneurysmal Rupture

Related Articles

Principled Technologies Releases Study Comparing a Year-Long Experience with Dell Technologies APEX Data Storage Services to a Similar Competitor Solution

Durham, NC, September 29, 2022 --(PR.com)-- Engaging a managed service provider to deliver a fully realized STaaS solution can increase agility and ease management burdens...

WatchGuard Threat Lab Reports Decrease in Malware Volume, Surge in Encrypted Malware and Actively Exploited Office Vulnerabilities

The Emotet comeback continues as threat actors target SCADA systems28 September 2022: The latest Internet Security Report from the WatchGuard Threat Lab, shows a...

Binmile Welcomes Edelweiss AMC to Its Clientele for Digital Advancement

Claymont, DE, September 28, 2022 --(PR.com)-- Binmile Technologies, a leading fintech software development company announces its partnership with Edelweiss ACM as their new client for...
Nashville, TN, September 15, 2022 –(PR.com)– Vesalio announces FDA HDE approval for commercialization of NeVa VS, indicated for the adjunct treatment of symptomatic cerebral vasospasm (CV) following aneurysmal subarachnoid hemorrhage (aSAH), the major cause of death and disability in this patient population. This is the first intracranial technology approved for this indication in the U.S.

CV is a potentially reversible life-threatening condition typically peaking 7 to 10 days after an intracranial hemorrhage caused by aneurysmal rupture (SAH). Vasospasm is the most common complication of SAH with occurrence rates of up to 70% according to publications. It is also known to be the leading cause of delayed morbidity and mortality.

To address this deadly condition, Vesalio leveraged expertise gained through the development of the NeVa™ stent retriever for thrombectomy in acute ischemic stroke. The NeVa VS is a proprietary device…

Read more…

Popular Articles